27 April 2009 - Archimedes Pharma, the pan-European specialty pharmaceutical company, today announced that it has submitted a centralised Marketing Authorisation Application with the European Medicines Evaluation Agency (EMEA) for approval of its lead development product, NasalFent, an innovative and highly differentiated fentanyl nasal spray for the rapid relief of breakthrough cancer pain.
The details can be read here.
No comments:
Post a Comment